Pulmonary HypertensionHeart and circulationLungs and breathing
What this study is
The objective of this observational pilot study is to collect HemoCept device data from subjects undergoing diagnostic right heart catheterization (RHC) procedures.
Study details
- Official title
- Observational Study of the HemoCept Device During Right Heart Catheterization at Boulder Heart
- Sponsor
- HemoCept Inc.
- Conditions
- Pulmonary Hypertension · Congestive Heart Failure(CHF) · Valve Disease, Heart
- Enrolling
- 50 people
- Starts
- 2025-12-01
- Est. completion
- 2026-03-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
- Subjects can be any gender but must be age 18 or older.
- Subject is able and willing to provide informed consent and HIPAA authorization.
- Subject is able and willing to meet all study requirements.
- Scheduled for a diagnostic right heart catheterization (RHC-only or combined RHC+LHC; left-heart-only procedures are not eligible)
You can't join if
- Subject is pregnant, breastfeeding, or intends to become pregnant during this study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openBoulder Heart
Boulder, Colorado, United States
- Katharine Adkins · Contact303-442-2395kathari.adkins@bch.org
- Scott Blois, MD · Principal investigator
Recruiting
Study team
Sponsor
HemoCept Inc.
Study ID PRT-020
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.